Medicare Part D plans and drug makers may apply to participate in a new payment model starting in January, which will allow plan sponsors to offer benefits that limit cost sharing for a 30-day supply of insulin to no more than $35. To encourage participation, the model will give qualifying plans that enroll a high number of insulin-dependent patients the option of additional risk corridor protection for calendar years 2021 and 2022. The model also will test how to encourage healthy behaviors and medication adherence through Part D reward and incentive programs. To participate, drug makers may apply through March 18 and Part D sponsors through May 1. CMS plans to make a list of participating drug makers available to Part D sponsors on or around March 20.

Related News Articles

Headline
A JAMA study published Aug. 18 found that plan design changes by Medicare Part D insurers, particularly for Medicare Advantage plans, following passage of the…
Headline
The Centers for Medicare & Medicaid Services has issued the 2025-2026 Medicaid Managed Care Rate Development Guide for states to use when setting managed…
Headline
The AHA today filed an amicus brief in the U.S. Court of Appeals for the D.C. Circuit, defending the Department of Health and Human Services’ decision to…
Headline
The Centers for Medicare & Medicaid Services Aug. 1 issued a final rule for the inpatient psychiatric facility prospective payment system for fiscal year…
Chairperson's File
Public
The recently enacted One Big Beautiful Bill Act will bring big changes to health care. AHA President and CEO Rick Pollack joined me for a Leadership Dialogue…
Headline
The House Ways and Means Subcommittees on Health and Oversight held a joint hearing today to discuss lessons learned, challenges and opportunities to improve…